TABLE 2.
Recipient outcomes, immunosuppression, and adverse events following islet and pancreas-after-islet transplant.
| Recipient | Initial HbA1c | Current HbA1c | Current Insulin | Initial GFR | Current GFR | Duration of EFA (days) | Current IS | Complications | Management | PAI Transplant | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rejection | Treatment | ||||||||||
| BELA-1 | 7.4 | 7.3 | 6 U Tresiba morning | 98 | 91 | Sirolimus/myfortic/ belacept | Oral mucosal lesions | ||||
| BELA-2 | 5.9 | 6 | None | 44 | 48 | Myfortic/belacept | EBV viremia, subnephrotic proteinuria | stopped sirolimus, proteinuria improved | |||
| BELA-3 | 6.9 | 7.4 | 10 U Tresiba morning, Aspart 2-3 U with meals (∼16–19 U/day) | 80 | 54 | None | Proteinuria, nonhealing leg wound in 2013 | Stop sirolimus, increase myfortic | |||
| BELA-4 | 8 | 5.7 | None | 75 | 26 | Tac/Everolimus/ Myfortic/ Prednisone | Bronchitis | Antibiotic therapy | No | N/A | |
| BELA-5 | 7.1 | 6.1 | 14 U determir at night, 2–3 U insulin regular with meals (∼20–23 U/day) | 41 | 8 | None | CMV esophagitis; cryptococcal meningitis | valgancyclovir, amphotericin/ flucytosine -> chronic fluconazole | |||
| EFA-1 | 6.9 | 6.7 | Lantus 10–12 U BID, humalog 28 –30 U (∼ 49–53 U/day) | 91 | 99 | 504 | None | None | N/A | ||
| EFA-2 | 6.8 | 6.1 | None | 50 | 41 | 568 | Sirolimus/myfortic | Intraperiotneal bleed; Thrush; UTI | None; antifungal therapy; antibiotic therapy | ||
| EFA-3 | 7.6 | 5.6 | None | 91 | 45 | 583 | Tac/Myfortic/ Prednisone | Peripancreatic abscess (PAI); Gastrointestinal distress, insomnia (PAI) | Percutaneous drainage, antibiotic therapy; dicsontinuation of mTOR inhibitor | Grade 1 ACR | Thymoglobulin, methylprednisolone |
| EFA-4 | 6.1 | 5.9 | None | 100 | 44 | 392 | None | Angioinvasive aspergillosis of the lung; CMV viremia; PTLD | Voriconazole, withdrawal of mTOR; valganyclovir and IS dose reduction; complete IS withdrawal, rituximab | ||
| EFA-5 | 6.7 | 5.1 | None | 95 | 46 | 804 | Tac/Myfortic/ Prednisone | Portal vein thrombus (islet); Facial squamous cell carcinoma (PAI) | Anticoagulation; Local resection | No | N/A |